Betrixaban (Bevyxxa): A Direct-Acting Oral Anticoagulant Factor Xa Inhibitor.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Oral direct thrombin inhibitors or oral factor Xa inhibitors versus conventional anticoagulants for the treatment of deep vein thrombosis.The Cochrane database of systematic reviews · 2023
   Pooled it
2. Haemostasis and the Need for Antithrombotics: An Introduction.Handbook of experimental pharmacology · 2026
   Review
3. Potential role of IGF-1/GLP-1 signaling activation in intracerebral hemorrhage.Current research in neurobiology · 2022
   Review
4. The Clinical Significance of Drug-Food Interactions of Direct Oral Anticoagulants.International journal of molecular sciences · 2021
   Review
5. Updates in Anticoagulation Therapy Monitoring.Biomedicines · 2021
   Review
6. Use of direct oral anticoagulants in ICU patients. Part I - Applied pharmacology.Anaesthesiology intensive therapy · 2021
   Review
7. Factors Affecting the Formation and Treatment of Thrombosis by Natural and Synthetic Compounds.International journal of molecular sciences · 2020
   Review
8. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach.Memorias do Instituto Oswaldo Cruz · 2020
   Article
9. A comparative analysis of the safety profile of direct oral anticoagulants using the FDA adverse event reporting system.European journal of haematology · 2019
   Article
10. Safety analysis of apixaban versus warfarin in patients with advanced kidney disease.Journal of thrombosis and thrombolysis · 2018
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

4 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract